Thank you Dudio for taking the time to complete a useful bit of analysis and share it with us
Any idea why it’s up 10%?
I agree matml. I can’t see the big pharmas not fighting it out to take this product for themselves. Broad spectrum anti viral and future pandemic stockpiling global sales will be impossible for them to resist.
Thanks Brent
cw25 - what does it mean "its in auction"? It looked like the order got split into 4 - does that mean they struggled to fill it?
A friend of mine just bought 40,000 shares at 141p at 9.55. Price has risen to 146p since then
Graking - I'm afraid you're so far off understanding the implications of the RNS thats its not worth explaining it
Surely this news would link in well with their article today on research into Long Covid getting a £10m boost?
How about some news on a UK company that has a drug now entering trials to see if it can mitigate the problem? As opposed to just studying how many peoples get it and how serious it is?
True in IMM, that’s been flat so far but hasn’t lost money either.
Yes her posts are bit rambling and manic but you can’t knock that she called a drop to 90p and then 80p when we were at 120p.
I’m not following her trades but I’m not filtering her either - unless there’s a number of calls made that don’t come to fruition and it comes to light that it’s just luck
likewise, I've managed to average down to 128p over the past month - so I'm hoping the weakness post vaccine trial results will be a blessing when I look back in 6 months time. I've only got half the shares you big players have though TL/Geo
It will last up to 5 years in super cold storage. Initially I'd assume it could only be used for covid-19 cases, since that is what it has been tested (and hopefully) proven to work against. However if further p3 trials were completed for other COPD then it could be used as a broad spectrum anti-viral.
The cost to stockpile for a government is peanuts compared to the money that is being spent on the impact of the pandemic
You could go down the MAP route instead via your doctor?
Eva - first of all congrats on your SNG share price calls recently. However, I have 55% of my SNG shares in an isa or Sipp - but that still leaves 45% in a standard account. The reason being that the allowance is too small to invest heavily in a particular company without selling all other ISA assets. So it’s a reasonable question to ask I feel.
TLwilliams - I think you're right about them being ultimately being acquired. I'm unsure at what point, but if its seems likely we have a proven broad spectrum anti-viral treatment on our hands then you can't imagine the big pharma's missing out on marketing that globally as the go to treatment for all viral pulmonary ailments.
If Tamiflu generated $3Bn per annum revenue then imagine what a treatment that actually worked could generate?
HL for me too. Good phone app and very good customer service. I've only ever had issues with them on the day the Pfizer vaccine got announced - as I think their IT infrastructure was overloaded. But I hear from others that use other platforms that they had a similar experience on that day.
scinv - to be fair, I dont think SNG approval will be dependent on a peer review of our P3 results either. Emergency approval may even come before then once we have meaningful interim p3 trial results
HarChris - Im not one of the long term experts but I didnt expect to see the SP be affected so significantly by vaccine news. However I have taken the SP weakness as an opportunity to buy more over the past month. This has brought my average SP down from £1.80 to £1.30 - as well as significantly increased my holding in the company so that it now makes up 30%+ of my investment portfolio.
No one has given a good reason why this wont be re-rated higher within the next 6 months, so I'm holding now and waiting patiently.
I'm confident that once we have the p3 results in a few months, there will still be new cases of covid requiring treatment. If its found from the extended trial assessments of patients that it also helps mitigate long covid then there is even more upside - who wouldn't want their doctor to prescribe SNG001 to them as soon as they were given a positive test result, even if they weren't in need of hospital care, if it was proven to prevent long covid?
On top of this, if its seen as a broad spectrum antiviral, then there is no danger of a government investment in a stockpile of the drug being a wasted investment. It can be used at any time for potentially any virus (presumably after further trials) within the next 5 years of the drugs shelf life
Prof Tom W: - dexamethasone with SNG001 treatment - suggestion that using SNG001 could assist with the dampening by dexa. P3 trial will include patients taking dexa so we will see.
Question - why cant providing this treatment to patients be sped up? - P2 trial too small to allow approval. P3 trial can prove efficacy and safety to a sufficient level. Regulators will move quickly with covid19, however SNG are moving at 'light speed' to get to this point of submitting for approval.
Question to Alex Horsley - Why was the Synairgen trial separate to Recovery trial? Answer - In recovery trial the focus was on using existing and available drugs.
Question to Tom W on Phase 3 - just about to start, still keen to recruit additional sites for the trial in the UK. First patients to be dosed in December, UK first. Hoping for expedited delivery of Phase 3.
Question to Tom W on Long Covid - Suggestion from p2 results that ongoing improvement from what could be seen at day 28 in trial. P3 will follow for longer to look for positive signal on helping with long covid.
Q to Tom W on ease of use of nebuliser - Switch to aerogen as its easier to self administer and easier to mass produce for clinical practice.
Q to Tom W on Emergency Use approval - constant and ongoing conversation. We dont have sufficient data yet - hence the p3 trial. What would be expedited is the approval once we have the data.
Prof Tom Phase 3 trial - "study is imminent and hopefully starting this year. We're in the final stages of planning."